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Abstract
We evaluated the concentrations of 25-hydroxyvitamin D [25(OH)D] in children and adolescents with juvenile systemic lupus
erythematosus (JSLE) and associated them with disease duration and activity, use of medication (chloroquine and
glucocorticoids), vitamin D intake, calcium and alkaline phosphatase levels, and bone mineral density. Thirty patients with
JSLE were evaluated and compared to 30 healthy individuals, who were age and gender matched. Assessment was performed
of clinical status, disease activity, anthropometry, laboratory markers, and bone mineral density. The 30 patients included 25
(83.3%) females and 16 (53.3%) Caucasians, with a mean age of 13.7 years. The mean age at diagnosis was 10.5 years and
mean disease duration was 3.4 years. Mean levels of calcium, albumin, and alkaline phosphatase were significantly lower in
patients with JSLE compared with controls (P,0.001, P=0.006, and P,0.001, respectively). Twenty-nine patients (97%) and
23 controls (77%) had 25(OH)D concentrations lower than 32 ng/mL, with significant differences between them (P,0.001).
Fifteen patients (50%) had vitamin D levels,20 ng/mL and 14 had vitamin D levels between 20 and 32 ng/mL. However, these
values were not associated with greater disease activity, higher levels of parathormone, medication intake, or bone mineral
density. Vitamin D concentrations were similar with regard to ethnic group, body mass index, height for age, and pubertal
stage. Significantly more frequently than in controls, we observed insufficient serum concentrations of 25(OH)D in patients with
JSLE; however, we did not observe any association with disease activity, higher levels of parathormone, lower levels of alkaline
phosphatase, use of medications, or bone mineral density alterations.
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Introduction
Vitamin D is the common denominator of a group of
steroids involved in the metabolism of a variety of tissues
and body systems. Its classical role is the regulation of
calcium homeostasis and bone formation and reabsorp-
tion through interaction with the parathyroid glands,
kidneys, and intestine (1). Over the past few years,
identification of 1a-hydroxylase and 24a-hydroxylase,
responsible for the production of 1,25-dihydroxycholecal-
ciferol [1,25(OH)2D], and the vitamin D receptors in the
cells for innate immunity highlighted the importance of this
micronutrient in immune regulation (2).
Vitamin D immunomodulatory effects are suppression
of adaptative immunity through a reduction in the
production of interleukin (IL)-2, gamma interferon, and
tumor necrosis factor, inhibition of expression of IL-6,
secretion and production of autoantibodies by B lympho-
cytes, and activation of innate immunity (3-6).
Epidemiological findings indicate that low 25-hydrox-
yvitamin D [25(OH)D] serum concentrations are asso-
ciated with the development of various diseases,
especially autoimmune diseases, including insulin-de-
pendent diabetes mellitus, multiple sclerosis, rheumatoid
arthritis, systemic lupus erythematosus (SLE), and
inflammatory bowel disease (5,6). Recent studies have
confirmed that most adult patients (7-11) and children and
adolescents with SLE have insufficient or deficient vitamin
D concentrations associated with disease activity (12).
The aim of this study was to evaluate the concentra-
tions of 25(OH)D in children and adolescents with juvenile
SLE (JSLE) and to associate them with disease duration
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and activity, use of medication (hydroxychloroquine and
glucocorticoids), vitamin D intake, calcium and alkaline
phosphatase levels, and bone mineral density.
Material and Methods
In a cross-sectional study, 30 patients with JSLE
according to Hochberg criteria (13) who were monitored in
the Pediatric Rheumatology outpatient clinic were eval-
uated during the spring of 2008. The inclusion criteria
were a minimum disease duration of 6 months. Patients
were excluded if they could not perform bone density
measurements due to incompatible stature (1), or if they
had other chronic diseases interfering with calcium,
phosphorus, and vitamin D metabolism, or if they did
not consent to participate in the study.
The control group consisted of 30 healthy individuals,
followed in a primary medical care facility, who were
gender and age (maximum difference of 6 months)
matched with the patients, who were not using supple-
ments containing vitamin D or calcium, and who had no
impairment in calcium, phosphorus, or vitamin D meta-
bolism.
Demographic, clinical, and treatment data were
collected from the patient charts from the visit closest to
the laboratory exams. The data for disease activity and
medications were also recorded. Anthropometric assess-
ment involved weight and height measurements, using
the reference proposed by the World Health Organization
(WHO) (14,15). Pubertal development was determined as
recommended by Marshall and Tanner (16).
Assessment of JSLE disease activity was performed
using the SLE Disease Activity Index 2000 (SLEDAI-2K)
(17). Disease activity was arbitrarily defined as SLEDAI-
2K .1 and .4.
Blood samples from the patients and controls were
collected in the morning after a 12-h fast for the following
tests: 25(OH)D, parathormone (PTH), serum calcium,
serum phosphorus, alkaline phosphatase, serum albumin,
serum urea, and serum creatinine. The patients were also
tested for ionized calcium, creatinine clearance, calciuria
and creatinuria in an isolated sample. The calciuria and
creatinuria ratio was considered abnormal if .0.2.
The concentration of 25(OH)D was measured by
electrochemiluminescence immunoassay using the com-
mercial kit Elecsys 25(OH)D3 assay (Modular Roche,
Brazil), and intact PTH was measured by immunofluori-
metric assay in 2009. The reference values for 25(OH)D
were as follows: ,20 ng/mL as deficiency, between 20
and 32 ng/mL as insufficiency, and .32 ng/mL as normal
(18). For PTH the normal range was from 15 to 65 pg/mL.
Serum phosphorus, serum calcium, serum urea,
serum albumin, isolated calciuria, creatinuria, and crea-
tinine clearance were measured by colorimetric analysis
(Modular Roche, Brazil), serum alkaline phosphatase was
measured by an enzyme activity method, and ionized
calcium was measured using a potentiometer.
Bone mineral density of the spine (L1-L4) was
measured by dual energy X-ray absorptiometry (DXA)
using a LUNARTM DPX-MD plus machine (GE-Lunar
Radiation Corporation, USA) equipped with pediatric
software (version 8.5) and adjusted to stature (19). The
variation coefficient for the spine, which was checked
daily according to the manufacturer’s specifications, was
2%.
The interval between the collection of medical records
and of blood exams and the measuring of bone mineral
density ranged from 0 to 90 days.
Statistical analyses were carried out with the statistical
software Minitab 15 (Minitab Inc., USA). To evaluate the
association between dichotomous variables, the chi-
square test was applied, and, when indicated, the Fisher
test was applied. The normality of continuous variables
was established by means of the Kolmogorov-Smirnov
test and reported as means±SD and the Student t-test
was used to compare them. When both variables were
symmetric, Pearson’s correlation coefficient was used. A
value of a ,5% was adopted (P,0.05).
Informed consent forms were signed by all patients
and controls and/or their legal guardians. The review
board of Universidade Federal de Sa˜o Paulo approved
the study protocol.
Results
Of the 30 children and adolescents with JSLE, 25
(83.3%) were female, 16 were Caucasian (53.3%), and
the current mean age was 13.7 years (7-18 years). The
mean age at diagnosis was 10.5 years (3-15 years) and
the mean disease duration was 3.4 years (0.5-12.2
years). All patients used sunblock and avoided exposure
to sunlight.
The control group consisted of 30 healthy volunteers,
25 were female (83.3%), 16 were Caucasian (53.3%) with
a mean age of 13.6 years (6-19 years). Table 1 displays
the characteristics of the groups studied.
Nineteen patients (63%) had renal involvement at the
time of diagnosis and 10 of 30 (33%) had renal disease
activity at the time of the evaluation. No patient had renal
function impairment. The calciuria/creatinuria ratio was
normal in all patients.
Mean 25(OH)D concentration in patients was signifi-
cantly lower than that observed in the controls (P,0.001;
Table 2). Fifteen patients (50%) and 6 controls (20%) had
25(OH)D deficiency, 14 patients (47%) and 17 controls
(57%) had 25(OH)D insufficiency, and only 1 patient (3%)
and 7 controls (23%) had sufficient concentrations of
25(OH)D. There was no significant difference between
groups regarding the mean PTH levels (P=0.268; Table
2).
Patients had a mean serum level of 1.29 mg/mL
ionized calcium (1.21-1.35 mg/mL; within normal range),
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Table 1. Characteristics of demographics, nutritional status and pubertal stage of
patients (n=30) with juvenile systemic lupus erythematosus (JSLE) and controls.
Variables JSLE
(n=30)
Controls
(n=30)
P
Age
Mean in years 13.7 13.6 0.846a
Range 7-18 6-19
Sex
Female 25 (83.3) 25 (83.3) 1.000b
Male 5 (16.7) 5 (16.7)
Ethnicity
Caucasian 16 (53.3) 16 (53.3) 1.000b
Non-Caucasian 14 (46.7) 14 (46.7)
Classification according to the BMI Z scorec
Adequate 17 (60.7) 26 (89.7) 0.011b
Not adequate 11 (39.3) 3 (10.3)
Classification according to the H/A Z scorec
Adequate stature 21 (75.0) 29 (100.0) 0.004b
Low stature 7 (25.0) 0 (0)
Pubertal stage
Pre-puberal 6 (20.0) 2 (7.0) 0.129b
Puberal 24 (80.0) 28 (93.0)
Data are reported as number with percent in parentheses except for age. BMI:
body mass index; H/A: height for age. aStudent t-test; bchi-square test. cNote: 2
patients and 1 control were older than 18 years, therefore they could not be
assessed by Z score.
Table 2. Serum concentrations of 25(OH)D and laboratory markers of patients
with juvenile systemic lupus erythematosus (JSLE) and controls.
JSLE
(n=30)
Controls
(n=30)
P
25(OH)D (ng/mL) 18.8 ± 7.3 27.2 ± 6.7 ,0.001a
(4.6-33.0) (15.2-39.4)
Insufficiency/deficiency (n) 29 23 0.023b
Deficiency (n) 15 6 0.015b
Parathormone (pg/mL) 35.9 ± 17.3 31.3 ± 14.4 0.268a
(14.2-79.1) (15.5-74.7)
Albumin (mg/dL) 4.2 ± 0.6 4.5 ± 0.3 0.006a
(2.3-5.0) (3.7-5.1)
Urea (mg/dL) 29.5 ± 11.2 22.4 ± 4.7 0.003a
(18.0-61.0) (16.0-34.0)
Creatinine (mg/dL) 0.62 ± 0.16 0.80 ± 0.15 ,0.001a
(0.4-1.2) (0.5-1.2)
Calcium (mg/dL) 9.2 ± 0.5 9.9 ± 0.51 ,0.001a
(7.7-9.8) (9.0-11.0)
Phosphorus (mg/dL) 4.2 ± 0.6 4.3 ± 0.7 0.743a
(3.3-5.5) (2.8-6.1)
Alkaline phosphatase (IU) 116.6 ± 67 256.4 ± 138.4 ,0.001a
(43.0-303.0) (63.0-560.0)
Data are reported as means±SD with range in parentheses unless otherwise
indicated. aStudent t-test; bchi-square test.
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which did not correlate with the 25(OH)D concentrations
(P=0.308).
Chloroquine was used by 28 patients (93%) and
glucocorticoids by 16 (53%), with a mean daily dose of
0.34 mg?kg-1?day-1 (0.03-0.78 mg?kg-1?day-1), mean
cumulative dose of 37,370 mg (1,000-149,430 mg), and
a mean duration of treatment of 32 months (4-132
months). Seventeen patients (57%) were taking calcium
and 11 (37%) were taking vitamin D supplements. Of
these 11 patients on vitamin D supplements, 5 had
deficient vitamin D concentrations, 5 had insufficient
concentrations, and only 1 had sufficient concentration
(P=0.705). Only one patient with low 25(OH)D concen-
tration had elevated PTH levels. We did not find a
correlation between vitamin D concentration and the use
of glucocorticoids, its daily and cumulative dose, and the
use of chloroquine (P=0.504; P=0.969; P=0.20;
P=0.455, respectively).
We did not find any association between 25(OH)D
concentration (>20 and,20 or>32 and,32 ng/mL) and
disease activity, for SLEDAI-2K .1 (P=0.705 and
P=0.366, respectively) or for SLEDAI-2K .4 (P=0.439
and P=1.00, respectively) and mean disease duration
longer or shorter/equal to 25 months (P=0.464).
Twelve (40%) patients had low bone mineral density
for their age. The abnormal values of DXA did not
associate with lower 25(OH)D concentrations (>20, ,20
or >32 and ,32 ng/mL, with P=0.710 and P=0.400,
respectively). However, there was a significant associa-
tion between cumulative glucocorticoid dose and low
bone mineral density (P,0.001).
We did not find an association between vitamin D
concentrations and ethnicity (Caucasian and non-
Caucasian; P=0.083), body mass index (BMI;
P=0.955), height for age ratio (P=0.646), or pubertal
stage (P=0.524).
We observed a positive correlation between 25(OH)D
concentrations and serum calcium levels (P=0.017 and
r=0.306) and serum albumin levels (P=0.01 and
r=0.316). For PTH, we found a trend toward an inverse
correlation with vitamin D concentrations (P=0.057 and
r= –0.247).
Discussion
Vitamin D deficiency is often seen in patients with SLE
(7-9). Wright et al. (12), when evaluating 38 individuals
with JSLE, observed a high frequency of severe vitamin D
deficiency (,10 ng/mL), with a significant difference
compared to controls. In our study, the frequency of
25(OH)D deficiency was 50%, with a significant difference
compared to controls. This percentage was higher than
that found by Wright et al. (12) and that described in a
study on adults with SLE (20).
A possible explanation for the elevated frequency of
deficiency/insufficiency that we observed may be the
season of sample collection, that is, spring. Although
Brazil is a tropical country, sunny all year, we cannot
exclude that, in the southern regions, winter and spring
are colder seasons, and this population is more protected
by winter clothing. Thudi et al. (21) reported 25(OH)D
concentrations lower than 32 ng/mL (80 nmol/L) in 65% of
the SLE patients, of Hispanic-American and African-
American origin, and the values found in winter and
spring were significantly lower than those in summer and
fall (21).
Photosensitivity and the consequent use of sunblock,
renal function impairment, presence of auto-antibodies
against vitamin D, and use of glucocorticoids are risk
factors for vitamin D deficiency in SLE patients (6,22). For
chloroquine, there is no consensus yet, and initial reports
point out that it may cause possible interference to vitamin
D metabolism, resulting in a lowering of its concentration
(23); however, a more recent study of patients with SLE
found a protective effect for this vitamin deficiency (20). In
our study, chloroquine was not associated with vitamin D
concentration or the use of glucocorticoids. Despite
vitamin D supplementation (doses of about 400 IU), we
did not observe any benefit on the prevention of this
vitamin deficiency.
There is no consensus in the literature on the ideal
vitamin D concentration. Recently, Abrams (24) sug-
gested that 25(OH)D concentrations greater than 20 ng/
mL would be sufficient to meet the needs of most children
and adults.
Gordon et al. (25) in 2008 evaluated 365 healthy
children and found 25(OH)D concentrations of ,20 ng/
mL in 12.1% and ,30 ng/mL in 40%. In a study
evaluating healthy North American children between
2001 and 2004, 9% deficiency and 61% insufficiency
were observed, i.e., 70% of the individuals had serum
concentrations lower than 32 ng/mL (26). According to
Greer (27), we should define the nutritional status related
to vitamin D based not only on 25(OH)D concentration,
but also on the genetic, environmental, and dietetic
factors involved with vitamin D and calcium and bone
mineralization.
Despite the high frequency of 25(OH)D deficiency that
we observed in JSLE patients, we did not verify a
significant alteration in levels of alkaline phosphatase,
PTH, or bone mineral density. The use of glucocorticoids
may have lowered the alkaline phosphatase levels.
Serum calcium was statistically lower in the patients
compared to the controls; however, an expected hyper-
phosphatemia due to low calcium levels did not occur, nor
did abnormal levels of ionized calcium.
In our study, we observed a direct and significant
correlation between vitamin D concentrations and serum
calcium levels. Although PTH levels did not show an
inverse correlation with vitamin D concentration, a trend
was observed. This proves that the action of PTH is often
stimulated when serum calcium levels are low due to a
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decrease in vitamin D (24,25,27).
Approximately one third of the patients had low bone
mineral density, however, without any association with
vitamin D concentration. Although this is an unexpected
finding, we know that low bone mineral density can be
influenced by other factors such as presence of inflam-
mation and use of glucocorticoids, and those factors may
explain this finding. Compeyrot-Lacassagne et al. (28)
evaluated a group of 64 patients with JSLE and found that
38% had low bone mass density for their age, a result
close to our findings of 40%. These authors also found a
significant association between cumulative glucocorticoid
dose and low bone mineral density (P,0.001), the same
as observed in our study.
Regarding disease activity and vitamin D deficiency,
the current data are controversial (11,20,29-31). Our
sample was characterized by JSLE patients with low
disease activity (mean value of SLEDAI-2K score was
4.4, 63.4% of the patients with SLEDAI-2K .1 and 33.4%
.4). Wright et al. (12) found an association between
vitamin D deficiency and greater disease activity; how-
ever, they could not establish a causal relationship
between them. Casella et al. (32) also found an
association between vitamin D deficiency and negative
effects on bone health and disease activity in a cohort of
pediatric lupus patients in spite of conventional vitamin D
supplementation. This finding was independent of therapy
and fat mass, and they suggested that those patients
might need higher doses of vitamin D supplementation.
Kamen et al. (22) suggested that vitamin D supplementa-
tion in SLE patients may have a beneficial effect on the
immune system in addition to the impact on bone
metabolism. There is still no consensus in the literature
on the vitamin D dosage to be supplemented in patients
with JSLE. Kamen (33) stated in a recent review paper
that a clinical trial comparing the use of 800 to 2000 or
4000 IU of vitamin D is in progress.
In the present study, BMI and height to age ratio did
not influence vitamin D concentration, and, when we
assessed only patients and controls with adequate weight
and stature, we found a significant difference regarding
their vitamin D concentrations.
It is well known that renal failure leads to limitations in
the conversion of inactive to active forms of vitamin D;
however, we did not observe renal impairment in any
patient, and this has not been an aggravating factor in
vitamin D concentrations (1,34).
Regarding ethnicity, it is known that non-Caucasians
usually have lower vitamin D concentrations due to
limitations in vitamin D production from solar exposure
in those individuals; however, we did not find a statistical
difference between the two races (1). This finding is
controversial, since our study population had a high
mixture of ethnicities, which hampered a precise classi-
fication.
There are some limitations in the present study, such
as the small sample size, the cross-sectional model used
which does not allow causal evaluations, and the lack of
DXA in the control group. Also, the method applied in the
determination of 25(OH)D concentrations may be ques-
tioned, as well as the values considered normal.
Finally, according to our findings, JSLE patients had
serum vitamin D concentrations significantly lower than
controls, without being associated with greater disease
activity, higher levels of PTH, or lower bone mineral
density.
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